The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
News
Gates streams $50m into Britain’s Dementia Discovery Fund
British venture the Dementia Discovery Fund (DDF) has received a $50 million investment from Bill Gates, to help fuel progress toward disease-modifying therapies for Alzheimer’s disease.
PharmaTimes Marketer & Communications Team of the Year Awards 2017: Winners announced
The PharmaTimes Marketer & Communications Team of the Year Awards 2017 took place last night at the London Marriott Hotel, Grosvenor Square.
NPL, Imperial College London launch new virtual lab
NPL and Imperial College London have unveiled a new £7 million virtual lab to help the UK’s synthetic biology industry enhance the manufacturing and adoption of new drugs, therapies and other products.
NHS England, Roche come to agreement on Perjeta
NHS England and Roche have agreed a confidential commercial agreement on the price of Perjeta for certain patients with breast cancer.
NICE backs Merck’s Mavenclad for MS
Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
Sanofi buys rights to Principia’s BTK inhibitor
Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm.
AZ books 3 percent sales drop for Q3
AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.
BI signs deal with MiNA to develop liver disease drugs
Boehringer Ingelheim has signed a second deal focused on the development of RNA therapeutics for liver diseases.
NICE brings on board Sigma to boost med tech uptake
The National Institute for Health and Care Excellence is linking with user experience agency Sigma to develop a new system to improve the identification of medical technologies for use in the NHS.
GSK confirms departure of R&D chief
Ending days of speculation GlaxoSmithKline has now confirmed the departure of its current R&D chief Patrick Vallance. The drugs giant has also presented new data for lupus drug Benlysta.
EFPIA urges co-operation to protect patients post Brexit
Nearly half (45 percent) of members of the European Federation of Pharmaceutical Industries and Associations members are expecting trade delays if the UK and Europe fail to reach a deal for Brexit.
Novartis ties with Royal Marsden to boost cancer care
Cancer patients living in North West and South West London are to benefit from a new Joint Working Project between Novartis and the Royal Marsden Partners Cancer Vanguard that aims to improve quality of care in the region by expanding the role of oncology pharmacists.
NICE turns down Bayer’s Stivarga for liver cancer
Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.
FDA OKs Roche’s Zelboraf for rare blood disease
US regulators have approved Roche’s Zelboraf (vemurafenib) for patients with a rare blood condition called Erdheim-Chester disease (ECD) carrying a mutation called BRAF V600
